胰岛素联合低分子肝素对妊娠期糖尿病患者的疗效

doi:10.3760/cma.j.issn.1007-1245.2023.21.008

摘要/Abstract

摘要：

目的　探究胰岛素联合低分子肝素对妊娠期糖尿病患者的疗效。方法　选取2019年2月至2020年1月于烟台市烟台山医院接受治疗的妊娠期糖尿病患者86例开展前瞻性研究，随机分为单独组、联合组各43例。单独组年龄（28.3±5.6）岁；初产妇27例，经产妇16例。联合组年龄（27.3±3.5）岁；初产妇25例，经产妇18例。单独组患者使用胰岛素进行治疗，联合组患者使用胰岛素联合低分子肝素进行治疗。对两组患者C反应蛋白（CRP）、脂蛋白相关磷脂酶A2（LpLA2）、血清胱抑素（CysC）、总胆红素（TBil）、总胆固醇（TC）、尿微量白蛋白（mAlb）、空腹胰岛素（FINS）、胰岛β细胞功能指数（HOMA-β）、胰岛素抵抗指数（HOMA-IR）、糖化血清蛋白（GSP）、空腹血糖（FBG）、糖化血红蛋白（HbA1c）进行检测并采用LSD-t检验比较，记录两组患者妊娠期并发症情况和新生儿情况并行χ²检验比较。结果　治疗后联合组患者血清CRP［（5.46±0.16）mg/L］、LpLA2［（96.25±4.17）U/L］、CysC［（0.73±0.18）mg/L］水平均低于单独组［CRP（8.49±0.38）mg/L、LpLA2（112.63±9.54）U/L、CysC（1.03±0.26）mg/L］（t=48.190、10.320、6.221，均P<0.001）。治疗后联合组患者TBil高于单独组［（11.76±3.87）μmol/L比（9.68±2.94）μmol/L］，TC［（2.64±0.83）mmol/L］、mAlb［（10.25±3.17）mg/L］水平均低于单独组［TC（3.65±1.12）mmol/L、mAlb（14.66±4.28）mg/L］（t=2.806、4.751、5.430，均P<0.05）。治疗后联合组患者FINS［（1.26±0.14）mU/L］、HOMA-IR［（2.57±0.16）］水平均低于单独组［FINS（1.52±0.42）mU/L、HOMA-IR（3.98±0.21）］，HOMA-β水平高于单独组［（65.20±5.86）比（51.14±4.35）］（t=3.851、35.022、12.633，均P<0.05）。治疗后联合组患者GSP［（191.69±10.14）μmol/L］、FBG［（3.21±1.06）mmol/L］、HbA1c［（3.98±0.18）%］水平均低于单独组［GSP（252.86±12.25）μmol/L、FBG（5.36±1.56）mmol/L、HbA1c（5.39±1.46）%］（t=25.224、7.475、6.285，均P<0.05）。治疗后联合组患者妊娠期并发症发生率［18.60%（8/43）］低于单独组［39.53%（17/43）］（χ²=4.568，P=0.033）。治疗后联合组患者新生儿不良情况总发生率［13.95%（6/43）］低于单独组［34.88%（15/43）］（χ²=5.103，P=0.024）。结论　使用胰岛素联合低分子肝素对妊娠期糖尿病患者进行治疗，可有效控制患者血糖和炎症因子，降低GSP、FBG、HbA1c水平，改善患者胰岛素抵抗和妊娠期结局和新生儿情况。

关键词:

胰岛素, 低分子肝素, 妊娠期糖尿病, 母婴结局

Abstract:

Objective　To explore the efficacy of insulin combined with low molecular weight heparin (LMWH) in patients with gestational diabetes mellitus. Methods　A prospective study was conducted on 86 patients with gestational diabetes mellitus treated in Yantai Mountain Hospital of Yantai City from February 2019 to January 2020, who were randomly divided into a single group and a combined group with 43 cases in each group. The age of the single group was (28.3±5.6) years old; there were 27 cases of primipara and 16 cases of multipara. The age of the combined group was (27.3±3.5) years old; there were 25 cases of primipara and 18 cases of multipara. The patients in the single group were treated with insulin, and the patients in the combined group were treated with insulin and LMWH. The C-reactive protein (CRP), lipoprotein-associated phospholipase A2 (LpLA2), serum cystatin (CysC), total bilirubin (TBil), total cholesterol (TC), urinary microalbumin (mAlb), fasting insulin (FINS), islet β cell function index (HOMA-β), insulin resistance index (HOMA-IR), glycosylated serum protein (GSP), fasting blood glucose (FBG), and glycosylated hemoglobin (HbA1c) were detected in the two groups and were compared by LSD-t test, and the pregnancy complications and neonatal conditions were recorded in the two groups and were compared by χ² test. Results　After treatment, the levels of serum CRP [(5.46±0.16) mg/L], LpLA2 [(96.25±4.17) U/L], and CysC [(0.73±0.18) mg/L] in the combined group were lower than those in the single group [CRP (8.49±0.38) mg/L, LpLA2 (112.63±9.54) U/L, and CysC (1.03±0.26) mg/L] (t=48.190, 10.320, and 6.221; all P<0.001). After treatment, the level of TBil in the combined group was higher than that in the single group [(11.76±3.87) μmol/L vs. (9.68±2.94) μmol/L], while the levels of TC [(2.64±0.83) mmol/L] and mAlb [(10.25±3.17) mg/L] were lower than those in the single group [TC (3.65±1.12) mmol/L and mAlb (14.66±4.28) mg/L] (t=2.806, 4.751, and 5.430; all P<0.05). After treatment, the levels of FINS [(1.26±0.14) mU/L] and HOMA-IR [(2.57±0.16)] in the combined group were lower than those in the single group [FINS (1.52±0.42) mU/L and HOMA-IR (3.98±0.21)], while the level of HOMA-β was higher than that in the single group [(65.20±5.86) vs. (51.14±4.35)] (t=3.851, 35.022, and 12.633; all P<0.05). After treatment, the levels of GSP [(191.69±10.14) μmol/L], FBG [(3.21±1.06) mmol/L], and HbA1c [(3.98±0.18)%] in the combined group were lower than those in the single group [GSP (252.86±12.25) μmol/L, FBG (5.36±1.56) mmol/L, and HbA1c (5.39±1.46)%] (t=25.224, 7.475, and 6.285; all P<0.05). After treatment, the incidence of pregnancy complications in the combined group [18.60% (8/43)] was lower than that in the single group [39.53% (17/43)] (χ²=4.568, P=0.033); the total incidence of adverse neonatal conditions in the combined group [13.95% (6/43)] was lower than that in the single group [34.88% (15/43)] (χ²=5.103, P=0.024). Conclusion　Insulin combined with LMWH can effectively control the blood glucose and inflammatory factors in patients with gestational diabetes mellitus, reduce the levels of GSP, FBG, and HbA1c, and improve the maternal insulin resistance, pregnancy outcomes, and neonatal conditions.

Key words:

Insulin, Low molecular weight heparin, Gestational diabetes mellitus, Maternal and infant outcomes

姜凌杨海燕刘荣慧姜萍宋美玉.

胰岛素联合低分子肝素对妊娠期糖尿病患者的疗效 [J]. 国际医药卫生导报, 2023, 29(21): 3017-3022.

Jiang Ling, Yang Haiyan, Liu Ronghui, Jiang Ping, Song Meiyu.

Efficacy of insulin combined with low molecular weight heparin in patients with gestational diabetes mellitus [J]. International Medicine and Health Guidance News, 2023, 29(21): 3017-3022.

参考文献

[1] 王蕤,徐品颖,肖利.妊娠期显性糖尿病与妊娠期糖尿病在妊娠晚期临床特点的比较[J].首都医科大学学报,2017,38(1):103-107. DOI:10.3969/j.issn.1006-7795.2017. 01.021.
[2] 杨莹,王金瑞.妊娠期糖尿病诊断标准的思考[J].医学与哲学,2018,39(4):8-13. DOI:10.12014/j.issn.1002-0772. 2018.02b.03.
[3] White SL, Begum S, Vieira MC, et al. Metabolic phenotyping by treatment modality in obese women with gestational diabetes suggests diverse pathophysiology: an exploratory study[J]. PLoS One, 2020, 15(4):e0230658. DOI: 10.1371/journal.pone.0230658.
[4] 张晶晶,顾平,马婉贞,等.妊娠期糖尿病孕期餐后血糖监测与妊娠结局相关性的研究进展[J].护士进修杂志,2019,34(12):1103-1106. DOI:10.16821/j.cnki.hsjx.2019. 12.010.
[5] Ortega-Senovilla H, Schaefer-Graf U, Herrera E. Correction to: pregnant women with gestational diabetes and with well controlled glucose levels have decreased concentrations of individual fatty acids in maternal and cord serum[J]. Diabetologia, 2020, 63(7):1435-1436. DOI: 10.1007/s00125-020-05136-1.
[6] 吴小绸,吴克亮,孙晓峰,等.在不同妊娠阶段妊娠期糖尿病孕妇的血清代谢组学的分析[J].中国临床药理学杂志,2019,35(22):2823-2826. DOI:10.13699/j.cnki.1001- 6821.2019.22.013.
[7] Guo YY, Li T, Liu H, et al. Circulating levels of Elabela and Apelin in the second and third trimesters of pregnancies with gestational diabetes mellitus[J]. Gynecol Endocrinol, 2020, 36(10):890-894. DOI: 10.1080/09513590.2020. 1739264.
[8] 陈雪蓉,沈冉,靳晴,等.血清ANGPTL4、ANGPTL6水平与妊娠期糖尿病胰岛素抵抗的相关性研究[J].中国计划生育学杂志,2019,27(12):1686-1689. DOI:10.3969/j.issn.1004- 8189.2019.12.029.
[9] 赵明,李光辉.妊娠期糖尿病孕妇的胰岛素抵抗和胰岛β细胞功能与巨大儿的相关性研究[J].中华内分泌代谢杂志,2019,35(10):848-852. DOI:10.3760/cma.j.issn.1000- 6699.2019.10.007.
[10] 李璐,徐安平,夏勇等.妊娠期糖尿病孕妇产后糖尿病发生的高危因子分析[J].中山大学学报(医学版),2018,39(4):626-630. DOI:10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2018.0085.
[11] Wang X, Ding Y, Zhang X, et al. The association between HHEX single-nucleotide polymorphism rs5015480 and gestational diabetes mellitus: a meta-analysis[J]. Medicine (Baltimore), 2020, 99(12):e19478. DOI: 10.1097/MD.0000000000019478.
[12] 李玉琴.妊娠期糖尿病的规范化治疗对妊娠结局的影响[J].中国现代医学杂志,2018,28(7):124-126. DOI:10.3969/j.issn.1005-8982.2018.07.026.
[13] 俞丽华.妊娠期糖尿病孕妇胰岛素分泌特点及母婴结局[J].中国计划生育学杂志,2019,27(6):752-755. DOI:10.3969/j.issn.1004-8189.2019.06.017.
[14] 黄铭钧,李瑞满.妊娠期糖尿病的影响因素及其对不良妊娠结局的影响[J].暨南大学学报(自然科学与医学版),2017,38(3):264-268. DOI:10.11778/j.jdxb.2017.03.013.
[15] 曾瑜,夏航彪,韩雨梅,等.尿IgG、mALB、β2-MG联合ACR预测妊娠期糖尿病孕妇早期肾功能损伤[J].中国计划生育学杂志,2022,30(7):1644-1647. DOI:10.3969/j.issn.1004- 8189.2022.07.040.
[16] 李庆,徐金玲,方红娟,等.妊娠期糖尿病患者血清IL-17、IL-1β、IL-10水平变化及其与胰岛素抵抗、血脂的关系[J].山东医药,2019,59(4):52-54. DOI:10.3969/j.issn.1002- 266X.2019.04.013.
[17] 叶华莹,李华萍.妊娠期糖尿病孕妇血脂与血糖状态及胰岛素抵抗的相关性分析[J].上海交通大学学报(医学版),2019,39(7):768-773. DOI:10.3969/j.issn.1674-8115.2019. 07.014.
[18] Miao Z, Wu H, Ren L, et al. Long-term postpartum outcomes of insulin resistance and β-cell function in women with previous gestational diabetes mellitus[J]. Int J Endocrinol, 2020, 2020:7417356. DOI: 10.1155/2020/7417356.
[19] 隆维东,朱艮苗,黄冬悦,等.血清超敏C反应蛋白与妊娠期糖尿病早期肾损伤的相关性研究[J].中国实验诊断学,2017,21(2):241-243. DOI:10.3969/j.issn.1007-4287. 2017.02.019.
[20] 魏青文,颜彬,龚丽娟.糖化血红蛋白、糖化血清蛋白、C反应蛋白联合检测对早期妊娠期糖尿病的诊断价值[J].中国计划生育和妇产科,2018,10(1):54-56. DOI:10.3969/j.issn.1674-4020.2018.01.15.
[21] 李霞,王彤,瓮占平,等.妊娠期糖尿病患者血清空腹血糖、餐后血糖、糖化血红蛋白情况及其与不良妊娠结局的关系研究[J].中国医刊,2022,57(1):57-60. DOI:10.3969/j.issn.1008-1070.2022.01.016.
[22] 沈磊芬,施卫琴,蔡丽文.孕早期FBG、HbA1c及孕前BMI对妊娠期糖尿病的联合诊断价值[J].中国妇幼健康研究,2021,32(2):205-208. DOI:10.3969/j.issn.1673-5293. 2021.02.007.
[23] Ren Z, Zhe D, Li Z, et al. Study on the correlation and predictive value of serum pregnancy-associated plasma protein A, triglyceride and serum 25-hydroxyvitamin D levels with gestational diabetes mellitus[J]. World J Clin Cases, 2020, 8(5):864-873. DOI: 10.12998/wjcc.v8.i5.864.
[24] 梁霞,姚漫漫,赵爱巧,等.尿白蛋白/肌酐比值与妊娠期糖尿病患者肾脏损伤的相关性研究[J].中国糖尿病杂志,2019,27(3):179-183. DOI:10.3969/j.issn.1006-6187.2019. 03.003.